Navigation Links
Lexapro Loses First-Line Position for the Treatment of Major Depression
Date:5/12/2009

Use of Atypicals In Major Depression Treatment Is Growing, According to a New Report from Decision Resources

Patient-Flow Forecasts Between Pristiq and Effexor XR Need to Take Into Account Reimbursement Hurdles

WALTHAM, Mass., May 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Forest Laboratories' Lexapro is no longer the leading first-line agent of choice for the treatment of major depression. Lexapro may have lost its first-line dominance because of the increasing frequency of step therapy restrictions requiring patients to first try therapy with citalopram (Forest Laboratories' Celexa, generics) before being reimbursed for Lexapro.

The new report entitled Treatment Algorithms in Major Depression also finds that although atypical antipsychotics do not capture substantial patient share until the third-line of therapy in newly diagnosed patients, third-line patient share has grown from 11.8 percent to 17.1 percent since last year's report. This growth is likely attributed to physicians' growing comfort with these agents given the FDA approval of Bristol-Myers Squibb/Otsuka's Abilify as an adjunct therapy in 2007 and the expected upcoming FDA approval of AstraZeneca's Seroquel XR for treating this disease.

"AstraZeneca's Seroquel, Pfizer's Geodon and Eli Lilly's Zyprexa all capture more patient share in the third line in our current analysis versus the analysis in our 2008 report. Even though these agents are not FDA-approved for major depression, physicians appear to be becoming more comfortable with atypicals as a class, a trend that may reflect a spill-over effect from Abilify's approval," stated Michael Malecki, Ph.D., analyst at Decision Resources.

By pairing patient-level claims data with primary survey data, the report can be used to build patient-flow models and highlight assumptions driving these models.

"Of all patients in our claims database taking Wyeth's Pristiq for major depression, only 2.6 percent took the drug on the first line. Among patients moving to Pristiq from another drug, 13.0 percent had taken Wyeth's Effexor XR on the previous line of therapy, indicating that Pristiq is drawing business from more than just Effexor XR," said Dr. Malecki. "Surveyed physicians point to better reimbursement of and greater familiarity with Effexor XR as the top reasons they choose this drug. This suggests that efforts made by Wyeth to move patients from Effexor XR to Pristiq over the next couple of years will have to overcome these hurdles. Likewise, any forecast patient-flow between these drugs will also have to take into account Pristiq's limitations."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from IMS Lifelink: Health Plans Claims database to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
2. Zoloft, Lexapro the Best of Newer Antidepressants
3. Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents
4. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
5. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
6. HEI, Inc. Closes on Sale of RFID Division Assets
7. Bally Total Fitness Emerges From Chapter 11 and Closes Transaction with Harbinger Capital Partners Funds
8. Actor Joe Pantoliano Discloses Depression; Talks About His Latest Movie and His Sensitive Side
9. Stryker Discloses Informal Inquiry Made by United States Securities and Exchange Commission
10. MediKeeper Closes Series A Financing Round with PacifiCap as Lead Investor
11. Nexia Closes Acquisition of Green Endeavors; Landis Salons On Track to Generate Revenues of $2.2 Million in 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Planet Fitness, one ... U.S., announced today its plans to open a flagship location in Covington, LA at ... former Rooms To Go store next to Office Depot in the Holiday Square shopping ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based ... and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored ... 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a ... targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , ...
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
(Date:9/12/2017)...  Consumer reviews on the independent review site Consumer Affairs ... company for hearing aids, ranking it higher than Miracle Ear ... ... For Hearing Aids ... online store that provides high performance, state-of-the-art, German-engineered hearing aids directly ...
Breaking Medicine Technology: